ALIAS 试验中白蛋白对局灶性脑缺血的神经保护作用:严重程度、机制和输注时机是否重要?
该分析合并 ALIAS I 和 II 试验共 1275 例患者,依据临床前研究特征筛选出心源性栓塞相关大梗死(NIHSS≥15)患者 189 例(白蛋白组 100 例、安慰剂组 89 例)。整体比较 3 个月极佳结局(mRS 0-1)无显著差异(OR 1.632,95%CI 0.719-3.708,P=0.2419)。按给药时间分层后,发病 2 小时内接受静脉白蛋白者 3 个月极佳结局的比值比显著升高(OR 9.369,95%CI 1.040-84.405,P=0.0461,校正年龄、性别、基线 NIHSS 评分及任何治疗操作)。作者认为这提示与临床前模型最接近的特定缺血性卒中亚组可能从该治疗中获益,并建议进一步开展临床试验按 NIHSS 严重程度分层和及时随机化。
要点
- 整体心源性栓塞性大梗死(NIHSS≥15)患者中,高剂量静脉白蛋白组(n=100)与安慰剂组(n=89)3 个月极佳结局(mRS 0-1)无显著差异:OR 1.632(95%CI 0.719-3.708),P=0.2419。
- 发病 2 小时内接受高剂量静脉白蛋白者,3 个月极佳结局的比值比显著升高:OR 9.369(95%CI 1.040-84.405),P=0.0461,校正年龄、性别、基线 NIHSS 评分及任何治疗操作。
- 该分析合并 ALIAS I 和 II 试验共 1275 例患者,仅筛选出心源性栓塞相关大梗死(NIHSS≥15)189 例进行亚组分析。
- 作者认为,与临床前模型最接近的特定缺血性卒中亚组可能从高剂量白蛋白治疗中获益,并建议进一步临床试验按 NIHSS 严重程度分层和及时随机化。
适用人群与场景
- 合并 ALIAS I 和 II 试验的缺血性卒中患者共 1275 例;本分析筛选出心源性栓塞病因相关的大面积缺血性卒中(NIHSS≥15)患者 189 例(白蛋白组 100 例、安慰剂组 89 例)。
诊断标准与关键阈值
- 大面积缺血性卒中定义:NIHSS≥15;病因分类为心源性栓塞。
- 极佳结局定义:3 个月时改良 Rankin 量表(mRS)评分 0-1 分。
处置流程与药物剂量
- 给药时机分层:发病 2 小时内接受静脉白蛋白输注者与 2 小时后输注者比较。
研究设计与关键结果
- 研究类型:对 ALIAS I 和 II 试验的合并分析;共 1275 例患者,筛选出心源性栓塞相关大梗死(NIHSS≥15)189 例。
- 主要结果:高剂量静脉白蛋白组(n=100)与安慰剂组(n=89)3 个月极佳结局(mRS 0-1)的比值比无显著差异:OR 1.632(95%CI 0.719-3.708),P=0.2419。
- 亚组结果:发病 2 小时内接受静脉白蛋白者 3 个月极佳结局的比值比显著升高:OR 9.369(95%CI 1.040-84.405),P=0.0461,校正年龄、性别、基线 NIHSS 评分及任何治疗操作。
证据类型、等级与局限
- 证据类型:对两项随机对照试验(ALIAS I 和 II)的合并分析;原文未给出证据等级或推荐强度。
- 局限:原文报告 ALIAS 试验未显示总体临床获益,且临床前研究模型未被完全遵循;本分析为亚组分析,作者认为可能需要进一步临床试验按 NIHSS 严重程度分层和及时随机化以评估该概念。
对床旁实践的改变
- 作者认为,对于心源性栓塞相关大梗死(NIHSS≥15)且在发病 2 小时内接受高剂量静脉白蛋白的缺血性卒中患者,可能获益于该治疗,但需进一步临床试验按 NIHSS 严重程度分层和及时随机化验证。
- 原文未据此给出常规推荐;整体人群(ALIAS 试验)未显示高剂量静脉白蛋白的总体临床获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine whether there is any differential benefit of albumin administration within 2 h of onset of ischemia and in settings (severe ischemia with reperfusion in cardioembolic strokes with National Institutes of Health Stroke Scale [NIHSS] ≥15), most representative of experimental models of cerebral ischemia in which albumin was effective in reducing neurological injury.
BACKGROUND: High-dose intravenous (IV) albumin treatment for acute ischemic stroke (ALIAS) trial did not show overall clinical benefit in ischemic stroke patients in contrast to preclinical studies; however, models of preclinical studies were not completely followed.
METHODS: A total of 1275 patients combined from ALIAS trials I and II were included in our analysis. We analyzed preclinical studies and selected patients with large ischemic stroke (NIHSS ≥15) related to cardioembolic etiology (n = 189). Outcomes were then studied including time from onset to IV albumin administration.
RESULTS: The odds of excellent outcome (mRS 0-1) at 3 months was not different with high-dose IV albumin infusion (n = 100) compared with placebo (n = 89) ((odds ratio [OR]) 1.632 [0.719-3.708], p value 0.2419). When we further classified these subjects according to time of IV albumin administration, we observed significantly higher odds of excellent outcome at 3 months when patients received IV albumin within 2 h, OR 9.369 (CI 1.040-84.405), p value 0.0461, after adjusting for age, gender, baseline NIHSS score, and any therapeutic procedure.
CONCLUSION: A trend for benefit is noted in ischemic stroke patients with large cardioembolic stroke (NIHSS ≥15) when high-dose albumin was initiated within 2 h, suggesting that certain ischemic stroke subgroups of patients most representative of preclinical settings may benefit from such a treatment. Additional clinical trials maybe needed to stratify subjects and treatment assignments according to NIHSS severity and timely randomization to evaluate this concept further.
参考来源
- Khatri R, Afzal MR, Rodriguez GJ, et al. Albumin-Induced Neuroprotection in Focal Cerebral Ischemia in the ALIAS Trial: Does Severity, Mechanism, and Time of Infusion Matter? Neurocrit Care. 2018. PMID: 28439774. doi:10.1007/s12028-017-0400-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。